Mirtazapine Milpharm Limited, (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine. It also antagonizes 5‑HT2 and 5‑HT3 serotonin receptors, enhancing serotonergic transmission through the 5‑HT1A pathway. This dual action contributes to mood elevation, reduced anxiety, and improved sleep.

The appropriate dose of mirtazapine is determined by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Dosage adjustments are individualized, and patients should follow the specific instructions provided by their healthcare professional.

The safety of mirtazapine in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine often produces stronger sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss. Its distinct receptor profile may also result in a different side‑effect spectrum, making it a useful alternative when SSRIs are not tolerated.

Mirtazapine Milpharm Limited tablets should be stored at ambient temperature, below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Mirtazapine is taken orally, usually once daily in the evening due to its sedative properties. The tablet should be swallowed whole with water and not chewed or crushed unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis or severe neutropenia, which can lead to infection, and rare cases of hepatotoxicity. Patients should be monitored for signs of infection, liver dysfunction, or any unexpected symptoms, and report them promptly to their clinician.

Mirtazapine should be avoided in patients with known hypersensitivity to the drug, those currently taking monoamine oxidase inhibitors, or individuals with severe hepatic impairment without appropriate dose adjustment. It is also contraindicated in patients with a history of agranulocytosis.